Guardant Health, Inc.
GH NASDAQHealthcare ★★★★★Latest Earnings Below forecast↓
Date
Jul 30, 2026
ET
EPS Est.
-0.76
EPS Actual
-0.90
Revenue Est.
$314.2M
Revenue Actual
$335M
Next Earnings Report
Date
Oct 28, 2026 · Wed
Time
After-market
Fiscal Period
FY2026 Q3
EPS Est.
-0.28
Revenue Est.
$349.3M
Company Overview
Guardant Health, Inc. (ticker GH) is listed on NASDAQ with a market cap of about $22.91B. Its next earnings report (FY2026 Q3) is expected on Oct 28, 2026 (ET), After-market, with consensus EPS of -0.28. In the last 15 reported quarters, EPS beat consensus estimates 6 times.
Actual EPS TrendRecently15Term · Feb 23, 2023 → Jul 30, 2026
Feb 23, 2023Range: -1.58 ~ -0.67Jul 30, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 30, 2026 | -- | -0.76 | Below forecast↓-0.90 | $314.2M | $335M |
| May 7, 2026 | -- | -0.81 | -0.85 | $279.2M | $301.7M |
| Feb 19, 2026 | -- | -0.77 | Below forecast↓-1.00 | $272.4M | $281.3M |
| Oct 29, 2025 | -- | -0.79 | -0.74 | $235.6M | $265.2M |
| Jul 30, 2025 | -- | -0.74 | -0.80 | $211.5M | $232.1M |
| Apr 30, 2025 | -- | -0.78 | -0.77 | $190.1M | $203.5M |
| Feb 20, 2025 | -- | -0.75 | Below forecast↓-0.90 | $192.1M | $201.8M |
| Nov 6, 2024 | -- | -0.55 | Below forecast↓-0.88 | $170.5M | $191.5M |
| Aug 7, 2024 | -- | -0.74 | -0.84 | $162.6M | $177.2M |
| May 9, 2024 | -- | -0.85 | -0.94 | $150.1M | $168.5M |
| Feb 22, 2024 | -- | -0.86 | Below forecast↓-1.58 | $149.6M | $155.1M |
| Nov 6, 2023 | -- | -0.95 | Above forecast↑-0.73 | $137.3M | $143M |
| Aug 3, 2023 | -- | -1.25 | Above forecast↑-0.67 | $129.8M | $137.2M |
| May 9, 2023 | -- | -1.32 | -1.30 | $117.9M | $128.7M |
| Feb 23, 2023 | -- | -1.37 | -1.36 | $123.8M | $126.9M |
Original Filings (SEC)
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
